Two concurrent multi-center phase 2 studies have confirmed the utility of using unrelated double umbilical cord blood (dUCB) or HLA-haploidentical donor bone marrow grafts in reduced-intensity hematopoietic cell transplantation (HCT). The two trials, conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), found 1-year overall and progression-free survival were 54% and 46%, respectively, after dUCB transplantation (n=50), and 62% and 48%, respectively, after haploidentical marrow transplantation (n=50). The authors note that because patients were not randomly assigned to one trial or the other, the outcomes cannot be compared directly. Rather, these two multi-center studies set the stage for BMT CTN 1101, a phase 3 randomized trial currently accruing participants, that will directly compare these transplant graft sources.
Parallel Phase 2 Trials Confirm Utility of Both Haploidentical and Cord Blood HCT